AuraSense Founded: 2009 Northwestern Inventor:
Post# of 182
(Total Views: 386)
Posted On: 04/06/2020 11:44:37 AM
AuraSense
Founded: 2009
Northwestern Inventor:
Chad Mirkin
Weinberg College of Arts and Sciences
Department of Chemistry
C. Shad Thaxton
Feinberg School of Medicine
Department of Urology
AuraSense's technology originates in the labs of Professors Chad A. Mirkin and C. Shad Thaxton at the Northwestern University International Institute for Nanotechnology. The Company's scientific founders and their developments have been the subject of over 80 national and international awards, 550 publications, and 930 patents.
AuraSense Therapeutics LLC
AuraSense Therapeutics, LLC is a privately held biopharmaceutical company founded by Professors Chad A. Mirkin and C. Shad Thaxton at Northwestern University. The Company is dedicated to developing and commercializing spherical nucleic acid (SNA™) conjugates. Its proprietary SNA constructs possess unparalleled biocompatibility and versatility as therapeutics, and they hold great promise for combating the world's most threatening diseases. The Company’s SNA technology overcomes the most difficult obstacles to gene regulation: genetic targeting with safe and effective in vivo performance.
Early SEC filings AuraSense
https://www.sec.gov/cgi-bin/browse-edgar?acti...efilings=0
Founded: 2009
Northwestern Inventor:
Chad Mirkin
Weinberg College of Arts and Sciences
Department of Chemistry
C. Shad Thaxton
Feinberg School of Medicine
Department of Urology
AuraSense's technology originates in the labs of Professors Chad A. Mirkin and C. Shad Thaxton at the Northwestern University International Institute for Nanotechnology. The Company's scientific founders and their developments have been the subject of over 80 national and international awards, 550 publications, and 930 patents.
AuraSense Therapeutics LLC
AuraSense Therapeutics, LLC is a privately held biopharmaceutical company founded by Professors Chad A. Mirkin and C. Shad Thaxton at Northwestern University. The Company is dedicated to developing and commercializing spherical nucleic acid (SNA™) conjugates. Its proprietary SNA constructs possess unparalleled biocompatibility and versatility as therapeutics, and they hold great promise for combating the world's most threatening diseases. The Company’s SNA technology overcomes the most difficult obstacles to gene regulation: genetic targeting with safe and effective in vivo performance.
Early SEC filings AuraSense
https://www.sec.gov/cgi-bin/browse-edgar?acti...efilings=0
(0)
(0)Exicure, Inc. (XCUR) Stock Research Links
Scroll down for more posts ▼